Please login to the form below

Not currently logged in
Email:
Password:

lesinurad

This page shows the latest lesinurad news and features for those working in and with pharma, biotech and healthcare.

Ironwood claims FDA OK for former AZ gout drug

Ironwood claims FDA OK for former AZ gout drug

Ironwood bought rights to Duzallo (allopurinol and lesinurad) and single-agent Zurampic (lesinurad) from AstraZeneca last year in a $265m deal, including $100m upfront, which came amid a massive slimming down ... In adult patients with gout who failed to

Latest news

More from news
Approximately 8 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.

  • Deal Watch June 2016 Deal Watch June 2016

    The deal also covers a fixed dose combination of lesinurad and allopurinol which is currently in clinical trials. ... licence. 270. AstraZeneca/ Grünenthal. Zurampic (lesinurad) and lesinurad fixed-dose combo with allopurinol for hyperuricaemia in

  • Deal Watch April 2016 Deal Watch April 2016

    450. AstraZeneca (UK). Ironwood (US). US license and commercialisation. Lesinurad (approved) combo in development for treatment of gout.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics